

Development and Evaluation of an Affordable HIV Viral Load Assay for use in Resource-Limited Settings

Abraham Alabi
Viral Diseases Programme
MRC Laboratories, Banjul, Gambia

EDCTP 4th Annual Forum
Ouagadougou, Burkina Faso

Presentation Outline:

- ❖ Introduction
- ❖ Assay Development
- ❖ Assay Validation
- ❖ Assay Implementation:
 - ❖ Projects
 - ❖ Capacity Building
- ❖ Conclusions
- ❖ Future Prospects
- ❖ Acknowledgement

Background

Increased resources in recent years mean more people in Resource-Poor Settings now have access to ART

Challenges

- High Cost of Rx Monitoring
- Inadequacy of trained health Personnel
- Lack of Infrastructure

Results

Inadequate Immunological & Virological Monitoring of patients on ART

Direct virological monitoring is achieved by measuring HIV viral load; however, there are limitations of commercial viral load assays:

- ❖ High cost
- ❖ Inadequate infrastructure & expertise
- ❖ Subtype variations
- ❖ Both HIV-1 & HIV-2 prevalent in West Africa and there is no commercial VL assay for HIV-2

Therefore, robust & cheap VL assays are needed to monitor viral control in clinical trials/intervention programmes

ASSAY DEVELOPMENT

- Received funding from EDCTP in 2004 and Project commenced in February 2005
- Developed a colorimetric format of an RT-PCR Assay for quantifying HIV RNA in human plasma

Principle:

The Assay is a quantitative reverse-transcribed PCR of the long terminal repeat (LTR) sequence of HIV in which test samples are quantified by comparison with a standard curve

Basic Procedure of Assay:

- Extraction of RNA from Patient's plasma
- Reverse transcription of RNA to cDNA
- PCR with specific HIV LTR primers
- Detection of DNA product by ELONA

Unique features of the Assay:

- Inclusion of internal calibrator to compensate for RNA loss, inhibition, RT-PCR & makes assay competitive
- Simple Technique
- Use of common Lab Equipment
- Affordable

Assay Validation (1)

Table 1. Differences in RNA copies/ml as determined by our HIV-1 colorimetric assay versus NIBSC expected values

<u>Sample</u>	<u>colorimetric</u>	<u>NIBSC</u>	<u>Log10 Diff.</u>
PWS-1	1055	1270	- 0.08
PWS-2	18467	12700	0.16
97/656	32676	35000	- 0.03
PWS-3	100	175	- 0.24


Mean Log Difference = **0.13**

Assay Validation (2)

15 HIV-2 positive plasma samples

Quantified by LDA & by Colorimetric assay

Figure 2. Relationship between RNA copies/ml ($\times 10^3$) as determined by our HIV-2 colorimetric assay and limiting dilution analysis (LDA)




Assay Validation (3)

10 HIV-1 positive plasma samples

Quantified by Roche & by Colorimetric assay

Figure 3. Relationship between RNA copies/ml as determined by our HIV-1 colorimetric assay and Roche amplicor assay (vs 1.5)



Assay Validation (4)


Table 2. Specificity of HIV-1 Assay

Sample	Sample ID	samples type	copies/ml
1	Neg. ctrl		<100
2	Pos. ctrl		5310
3	N004007	HTLV+ve, HIV-ve	<100
4	N004008	HTLV+ve, HIV-ve	<100
5	N004072	HTLV+ve, HIV-ve	<100
6	N027158	HIV2+ve, HIV-1-ve	<100
7	N027160	HIV2+ve, HIV-1-ve	<100
8	N027180	HIV2+ve, HIV-1-ve	<100
9	N027238	HIV2+ve, HIV-1-ve	<100
10	MVA-190	Hep.B+ve, HIV-ve	<100
11	MVA-197	Hep.B+ve, HIV-ve	<100
12	MVA-373	Hep.B+ve, HIV-ve	<100

Fig. 4 Validity of an Assay Run

Raw data

	1	2	3	4
A	5643	38547		
B	5403	38099		
C	19498	19119		
D	21014	19518		
E	30318	4397	12567	21136
F	29937	4549	13015	20496
G	33587	894.1	24.6	43999
H	37554	1067	34.7	17928




Sample	Sample ID	Sample date	samples type	copies/ml
1				<100
2				2223

Assay Implementation

How do we know the
medications are working

Before Rx On Rx



22/10/2007

APPLICATIONS OF OUR HIV VIRAL LOAD ASSAY (1)

1. HIV Pathogenesis & Transmission:

- High VL correlates with higher Transmission rates (O'Donovan et al., 2000)
- High baseline VL correlates with poor prognosis (Alabi et al., 2003)
- VL Dynamics in HIV-1 & HIV-2 Dual Infections

2. Treatment Monitoring:

- Initiation & modification of antiviral treatment
- Efficacy of Rx Regimens
- Early recognition of resistance development

APPLICATIONS OF OUR HIV VIRAL LOAD ASSAY (2)

HAART in Gambia

- HAART became available in The Gambia in Oct 2004 through the Global Fund for AIDS, TB and Malaria.
- The MRC is one of the main centres in Gambia where these drugs are available.
- Other centres are RVTH and HOC

APPLICATIONS OF OUR HIV VIRAL LOAD ASSAY (3)

Drug combinations in our GUM

HIV-1:

AZT or D4T+3TC+NVP

HIV-2 or HIV-Dual:


AZT or D4T+3TC+Kaletra(LPV/Rit)

APPLICATION OF OUR HIV VIRAL LOAD ASSAY (4)

HIV-1 vl undetectable after 12 wks on HAART

HIV-2 vl undetectable after 24 wks on HAART

Figure 4. Changes in viral load in HIV-1 and HIV-2 patients on highly active antiretroviral therapy (HAART)




APPLICATION OF OUR HIV VIRAL LOAD ASSAY (5)

HIV-1 vI
undetectable
after 12 wks on
HAART

HIV-2 vI
undetectable
after 3 wks on
HAART

Fig 8. VL changes in 19813502 (HIV-D) after 12 weeks on HAART



Capacity Building/Training

1. WEST AFRICA SUB-REGIONAL TRAINING ON HIV VIRAL LOAD ASSAY, SEPTEMBER 18-22, 2006, MRC LABORATORIES, BANJUL, GAMBIA
2. SOUTHERN AFRICA REGIONAL TRAINING ON HIV VIRAL LOAD ASSAY, SEPTEMBER 24-28, 2007, KENYA MEDICAL RESEARCH INSTITUTE (KEMRI), NAIROBI, KENYA

PARTICIPANTS AT VIRAL LOAD TRAINING, KEMRI, NAIROBI



Existing & Proposed Networks

North-South:

- ❖ A Collaboration on HIV-2 infection in Europe (ACHleV₂E)
- a multisite project to evaluate various HIV-2 assays in Europe (coordinator: Bernard Antoine, Bordeaux, France)

South-South:

- ❖ Collaboration with Gambia's National AIDS Programme
- ❖ Scientists/Institutions that participated in sub-regional Training Workshop, September 18-22, 2006
- ❖ Scientists/Institutions that participated in Regional Training Workshop, September 24-28, 2007

Conclusions

Cheap high through-put assay developed

Lots of successes

Marketable product

Low cost compared to other assays


User friendly assay

FUTURE PROSPECTS

- * Conduct a multi-centre evaluation
- * Evaluate assay for HIV subtypes
- * Possibly commercialise assay

APPLICATION OF OUR HIV VIRAL LOAD ASSAY (5)

Figure 5. Monthly viral load tests for HIV patients on highly active antiretroviral therapy (HAART) in our clinic cohort



Acknowledgement

MRC, Banjul

Clayton Onyango

Modou Camara

Pa Saidou Chaw

Sam MacConkey

Steve Kaye

Hilton Whittle

Sarah Rowland-Jones

Tumani Corrah

NIBSC, London

Neil Berry

Harry Holmes



EDCTP

HIV TRANSMISSION

The most common methods of transmission of HIV are:



Unprotected sex with an infected partner



Sharing needles with infected person

Almost eliminated as risk factors for HIV transmission are:



Transmission from infected mother to fetus



Infection from blood products

ADAM.

Every 14 seconds a person between 15 and 24 years old is infected with HIV virus, accounting for half all new cases of the disease - U.N. Population Fund 2006